How many organs could you donate and remain alive? How many planet Earths could fit inside the Sun? How high is a giraffe's blood pressure? Why is the sea blue? To find out, Ask The Naked Scientists!
…
continue reading
Indhold leveret af Sano Genetics. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Sano Genetics eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
Player FM - Podcast-app
Gå offline med appen Player FM !
Gå offline med appen Player FM !
EP 112: Making the leap: the scientists collaborating to transform genetic targets into next generation treatments, with David Ochoa
MP3•Episode hjem
Manage episode 385370197 series 2631947
Indhold leveret af Sano Genetics. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Sano Genetics eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
This week on The Genetics Podcast Patrick is joined by David Ochoa, Platform Coordinator at Open Targets. They discuss how the Open Targets platform is enabling game-changing collaboration between academic research and big pharma. Working with partners including Sanofi, GlaxoSmithKline, Bristol Myers Squibb, Genentech and Pfizer, Open Targets powers collaboration between some of the world’s biggest drug development pioneers and most renowned academic institutions with the goal of accelerating production of effective drug treatments.
But while the pre competitive approach enables huge time and money savings for all stakeholders, it relies on effective coordination and alignment - David explains how Open Targets tackles the inherent challenges to allow this world-leading consortium to build the future of next generation treatments.
00:03 Introduction
But while the pre competitive approach enables huge time and money savings for all stakeholders, it relies on effective coordination and alignment - David explains how Open Targets tackles the inherent challenges to allow this world-leading consortium to build the future of next generation treatments.
00:03 Introduction
04:33 The types of data sets used for target discovery
08:08 Managing the heterogeneity of data sets
13:29 David Ochoa's career trajectory, and entry into Open Targets
18:28 Addressability of diseases and targets by different modalities
22:24 Retrospective analysis of genetic evidence in drug approvals
36:58 Future focus on revamping Open Targets genetics
39:54 Exploring somatic variation and mutational scanning
42:49 Clinical trial stoppage
48:22 Closing remarks
179 episoder
MP3•Episode hjem
Manage episode 385370197 series 2631947
Indhold leveret af Sano Genetics. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Sano Genetics eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
This week on The Genetics Podcast Patrick is joined by David Ochoa, Platform Coordinator at Open Targets. They discuss how the Open Targets platform is enabling game-changing collaboration between academic research and big pharma. Working with partners including Sanofi, GlaxoSmithKline, Bristol Myers Squibb, Genentech and Pfizer, Open Targets powers collaboration between some of the world’s biggest drug development pioneers and most renowned academic institutions with the goal of accelerating production of effective drug treatments.
But while the pre competitive approach enables huge time and money savings for all stakeholders, it relies on effective coordination and alignment - David explains how Open Targets tackles the inherent challenges to allow this world-leading consortium to build the future of next generation treatments.
00:03 Introduction
But while the pre competitive approach enables huge time and money savings for all stakeholders, it relies on effective coordination and alignment - David explains how Open Targets tackles the inherent challenges to allow this world-leading consortium to build the future of next generation treatments.
00:03 Introduction
04:33 The types of data sets used for target discovery
08:08 Managing the heterogeneity of data sets
13:29 David Ochoa's career trajectory, and entry into Open Targets
18:28 Addressability of diseases and targets by different modalities
22:24 Retrospective analysis of genetic evidence in drug approvals
36:58 Future focus on revamping Open Targets genetics
39:54 Exploring somatic variation and mutational scanning
42:49 Clinical trial stoppage
48:22 Closing remarks
179 episoder
Alle episoder
×Velkommen til Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.